posted
Lifeline Biotechnologies Files 510(k) Application with the Food and Drug Administration for the MastaScope(TM) Thursday November 17, 8:30 am ET RENO, Nev.--(BUSINESS WIRE)--Nov. 17, 2005--Lifeline Biotechnologies (Pink Sheets: LBTN - News) announced today that the Company has filed a 510(k) Pre-market Notification with the FDA, for the MastaScope(TM) product line. The FDA approval process is expected to take several months to complete. The MastaScope(TM) is a microendoscope that is utilized by physicians to observe the interior of women's breast milk ducts when examining for abnormalities, in particular, nipple discharge. The majority of breast cancers originate in the milk ducts. It is anticipated that this product and process of examination, will assist in the early detection of breast cancer and holds the prospect of reducing unnecessary exploratory surgeries. Dr. Mokbel, Lifeline principal investigator has stated that "For every 100 nipple discharge cases, one instance of breast cancer is found." The prospect of the MastaScope holds the potential of reducing unnecessary exploratory surgeries. "We knew that eventually we would need to complete this 510(k) once the MastaScope(TM) advanced from research and development to marketing and sales. We are very excited about the potential future of the MastaScope(TM)," stated Jim Holmes, CEO of Lifeline Biotechnologies About Lifeline Biotechnologies, Inc. Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company. More information is available at the company's website: www.lbti.com. Safe Harbor This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Contact: For Lifeline Biotechnologies, Inc. Big Apple Consulting USA, Inc. Matt Maguire, 407-884-0444 or 1-866-THE-APPLE
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
